ArticleJournal of virology2019
Development of Stable Rotavirus Reporter Expression Systems.
Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- Probing the sequence constraints for the stable incorporation of chimeric NSP1 segments into infectious rotaviruses.The Journal of general virology · 2026Article
- A rotavirus vaccine candidate attenuated by codon deoptimization protects neonatal mice against wild-type virus infection.PLoS pathogens · 2026Article
- Review
- Generation of G9 genotype porcine rotavirus using reverse genetics system and its application for antiviral screen and vaccine development.Virologica Sinica · 2026Article
- Single-round infectious rotaviruses with deletions of VP7 or VP4 genes, based on SA11 and WC3 strain backbones, and their potential use as viral vectors.PLoS pathogens · 2025Article
- Article
- Rotavirus Reverse Genetics Systems and Oral Vaccine Delivery Vectors for Mucosal Vaccination.Microorganisms · 2025Review
- Establishment of reverse genetics systems for Colorado tick fever virus.PLoS pathogens · 2025Article
- Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025Review
- Rapid production of recombinant rotaviruses by overexpression of NSP2 and NSP5 genes with modified nucleotide sequences.Journal of virology · 2024Article
- Efficient and robust reverse genetics system for bovine rotavirus generation and its application for antiviral screening.Virologica Sinica · 2024Article
- Novel transcription and replication-competent virus-like particles system modelling the Nipah virus life cycle.Emerging microbes & infections · 2024Article
- Generation of single-round infectious rotavirus with a mutation in the intermediate capsid protein VP6.Journal of virology · 2024Article
- Article
- Production of OSU G5P[7] Porcine Rotavirus Expressing a Fluorescent Reporter via Reverse Genetics.Viruses · 2024Article
- Recombinant rotavirus expressing the glycosylated S1 protein of SARS-CoV-2.The Journal of general virology · 2023Article
- Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- N-Glycosylation of Rotavirus NSP4 Protein Affects Viral Replication and Pathogenesis.Journal of virology · 2023Article
- Characterization of Sialic Acid-Independent Simian Rotavirus Mutants in Viral Infection and Pathogenesis.Journal of virology · 2023Article
- Monitoring Virus-Induced Stress Granule Dynamics Using Long-Term Live-Cell Imaging.Methods in molecular biology (Clifton, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered recombinant viruses expressing reporter genes have been developed for real-time monitoring of replication and for mass screening of antiviral inhibitors. Recently, we reported using a reverse genetics system to develop the first recombinant reporter rotaviruses (RVs) that expressed NanoLuc (NLuc) luciferase. Here, we describe a strategy for developing stable reporter RVs expressing luciferase and green or red fluorescent proteins. The reporter genes were inserted into the open reading frame of NSP1 and expressed as a fusion with an NSP1 peptide consisting of amino acids 1 to 27. The stability of foreign genes within the reporter RV strains harboring a shorter chimeric NSP1-reporter gene was greater than that of those in the original reporter RV strain, independent of the transgene inserted. The improved reporter RV was used to screen for neutralizing monoclonal antibodies (MAbs). Sequence analysis of escape mutants from one MAb clone (clone 29) identified an amino acid substitution (arginine to glycine) at position 441 in the VP4 protein, which resides within neutralizing epitope 5-1 in the VP5* fragment. Furthermore, to express a native reporter protein lacking NSP1 amino acids 1 to 27, the 5'- and 3'-terminal region sequences were modified to restore the predicted secondary RNA structure of the NSP1-reporter chimeric gene. These data demonstrate the utility of reporter RVs for live monitoring of RV infections and also suggest further applications (e.g., RV vaccine vectors, which can induce mucosal immunity against intestinal pathogens).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.